Dr. Dayan Goodenowe is a PhD neuroscientist, biochemist, synthetic organic chemist, inventor, and clinical research expert. In 1999, he invented and patented a revolutionary ion cyclotron resonance mass spectrometry technology that made it possible to monitor human biochemistry comprehensively for the first time in history.
Using this advanced technology, Dr. Goodenowe analyzed blood samples from tens of thousands of persons of all ages, of all races, and from multiple countries. A diverse range of over 20 diseases, from autism to dementia and from colon cancer to heart disease, was studied. The biochemistry of young versus old and all-cause mortality was studied. These research led to his discovery that early mortality and each human disease has a biochemical prodrome.
A biochemical prodrome is a deviation from health that precedes and is predictive of a future adverse health event such as disease or death.
These discoveries led to an extensive patent portfolio of diagnostic tests for the early detection and screening of diseases such as specific cancers (colon, pancreatic, ovarian, breast, lung, prostate, and many more), autism, multiple sclerosis, Parkinson’s, ALS, Alzheimer’s, dementia, bipolar disease, schizophrenia, unipolar depression, cardiovascular disease, and others. Dr. Goodenowe created the ProdromeSCAN™ blood test, which measures all of the key prodrome biomarkers and offers advanced laboratory test interpretation training for health practitioners
Harnessing the power of Prodrome Science
Dr. Goodenowe’s discovery of disease prodromes also revealed an opposite truth: people who maintained optimal biochemical health had an extremely low risk of disease – they had biochemical prodromes of health and longevity. The mission of Prodrome Science is to enable each and every person to attain biochemical prodromes of health using scientifically validated, targeted biochemical nutrition.
Biochemical prodromes of disease are detectable years in advance of disease symptoms. By converting disease prodromes into health prodromes, we can prevent future diseases — a victory with no battle.
The most devastating negative health prodrome discovered by Dr. Goodenowe was a deficiency in a critical group of lipids called plasmalogens. Dr. Goodenowe discovered that plasmalogen deficiencies are linked to numerous diseases such as Alzheimer’s, autism, multiple sclerosis, most cancers, and early death.
There is no viable dietary source of plasmalogens to restore plasmalogen deficiencies. Dr. Goodenowe was the first to design, invent, patent, and develop targeted plasmalogen precursors capable of restoring plasmalogens in all cells of the body.
Dr. Goodenowe’s plasmalogen precursors have been extensively studied in preclinical and clinical research and are now available as dietary supplements, ProdromeNEURO™ and ProdromeGLIA™ on Prodrome.com. Blood plasmalogen levels can be measured using Dr. Goodenowe’s ProdromeSCAN™ blood test.
Please contact us, if you are interested in our services.
Prodrome Japan (headquarters: Osaka City) started in 2024 as a company responsible for the Japanese health business of the Dr. Goodenowe Group headquartered in US.
Prodrome” is a pre-disease stage called a biochemical precursor state, which is not a disease. Through our services, we aim to contribute to improving people’s health and quality of life by recognizing them early and restoring them to a state of wellness.
We are very happy to be able to share the evidence based on Dr. Goodenowe’s innovative technology and knowledge with the people of Japan.
Prodrome Japan Inc.
Co-representative, Yasuyo Yamazaki
English 
日本語